Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.079 | 0.7 |
mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.7 |
mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.7 |